
AI Coverage
about 12 hours ago
Top Five Radiology Video Interviews in September 20264 days ago
Advances in AI — September 2026Latest News

ASTRO: What New Phase 3 Research Reveals About SBRT for Patients with Localized Prostate Cancer

Top Five Radiology Video Interviews in September 2026

Radiology and Building the Alzheimer’s Care Pathway of the Future

Can Brain MRI Surveillance Alone Be Advantageous in Monitoring Cognition for Patients with SCLC?

The Grouser in the Radiology Reading Room

Shorts










Podcasts
Videos
All News

Catch up on the top radiology content of the past week.

In a recent interview, Shadpour Demehri, MD, discussed new research examining connections between deep learning assessment of bone mineral density on chest CT, brain MRI data and the potential for enhanced risk stratification in patients with diabetes.

Catch up on the top AI-related news and research in radiology over the past month.

A deep learning model developed for predicting BI-RADS assessments from dynamic contrast-enhanced (DCE) breast MRI had over a 14 percent lower AUC than radiologist evaluation in external validation testing.

While better imaging may reduce the need for additional diagnostic tests, it may also eliminate the reimbursement that comes with those additional tests.

Offering telescoping and high-flow configurations, the TriNav Advance device reportedly provides interventional radiologists with improved access to small distal vessels during liver embolization procedures.

The CARE Chest X-Ray (CXR) Triage software reportedly bolsters consistent flagging of suspicious chest X-rays for lung collapse and pneumomediastinum across reviewing readers of different experience levels.

In a study involving over 700 participants who had chest CT and brain MRI, those with diabetes and lower vertebral bone mineral density (vBMD) had a nearly five percent faster total accumulation of white matter hyperintensity (WMH) in comparison to those without diabetes.

Indicated for the treatment of foregut, midgut and hindgut neuroendocrine tumors, the radiopharmaceutical Bravnetsa is reportedly bioequivalent and therapeutically equivalent to the previously FDA-approved Lutathera.

Newly cleared findings for the adjunctive AI platform a2z-Abdo-Triage include acute appendicitis, renal traumatic injury, ureteral stone and retroperitoneal hematoma.

Can MRI-Derived Tumor Habitat Subregions Bolster Recurrence Risk Stratification in Stage 2 and 3 Breast Cancer Cases?
In multivariable external testing, tumor structure habitat phenotypes from pre-treatment MRI revealed more than a doubling of recurrence risk for women with stage 2 and stage 3 breast cancer.

Could a la carte pricing be a consideration in improving revenue for radiologists in private practice?

Catch up on a variety of FDA news in radiology from the past week.

Catch up on the top radiology content of the past week.

























